## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Original) A drug delivery liposome composition for delivering a substance to be administered to a target site, which comprises an oligosaccharide coated liposome and a substance to be administered.
- 2. (Original) The drug delivery liposome composition of claim 1 wherein the oligosaccharide is oligomannose.
- 3. (Currently Amended) The drug delivery liposome composition of claim1 or 2 wherein the oligosaccharide is mannopentaose or mannotriose.
- 4. (Currently Amended) The drug delivery liposome composition of <u>claim</u>

  <u>1 any of claims 1 to 3</u> wherein the substance to be administered is a drug, marker or contrast medium.
- 5. (Original) The drug delivery liposome composition of claim 4 wherein the drug is an anti-cancer drug.

- 6. (Currently Amended) The drug delivery liposome composition of <u>claim</u>

  <u>1 any of claims 1 to 5</u> which is administered intraperitoneally, taken up by macrophage in the peritoneal cavity and delivered to a target site.
- 7. (Currently Amended) The drug delivery liposome composition of <u>claim</u>

  <u>1 any of claims 1 to 6</u> wherein the target site is the greater omentum and the extranodal small lymphatic tissue in the mesentery, which are the early intraperitoneal metastasis lesions for cancer.
- 8. (Currently Amended) The drug delivery liposome composition of <u>claim</u>

  <u>1 any of claims 1 to 7</u> which is administered in combination with oligosaccharide coated liposome encapsulating a magnetic compound.